Miake Junichiro
Division of Pharmacology, Department of Pathophysiological and Therapeutic Science, School of Medicine, Faculty of Medicine, Tottori University, Yonago 683-8503, Japan.
Yonago Acta Med. 2020 Jul 13;63(3):146-153. doi: 10.33160/yam.2020.08.002. eCollection 2020 Aug.
Although there are many reports on the regulation of ion channel expression in transcription and translation, few drugs have been studied to influence post-translational modification of ion channel proteins. The Kv1.5 channel is a potassium ion channel expressed in atrial muscle, belongs to the voltage-gated K channel superfamily, and forms an ultrarapid delayed rectifier potassium ion current. It is important to understand the fate of these channel proteins, as cardiac Kv1.5 mutations can cause arrhythmias. Disruption of quantitative and qualitative control mechanisms of channels leads to stagnation and degradation of intracellular channel proteins. As a result, ion channel proteins are not transported to the cell membrane and are involved in the development of atrial fibrillation. This review takes the Kv1.5 channel as an example and focuses on the degradation mechanism of ion channel proteins, and discusses its application to the treatment of arrhythmia by drugs that control the mechanism of ion channel protein degradation.
尽管关于离子通道表达在转录和翻译水平的调控已有许多报道,但针对影响离子通道蛋白翻译后修饰的药物研究却很少。Kv1.5通道是一种在心房肌中表达的钾离子通道,属于电压门控钾通道超家族,可形成超快速延迟整流钾离子电流。了解这些通道蛋白的命运很重要,因为心脏Kv1.5突变可导致心律失常。通道定量和定性控制机制的破坏会导致细胞内通道蛋白的停滞和降解。结果,离子通道蛋白无法转运到细胞膜,并参与心房颤动的发生发展。本综述以Kv1.5通道为例,重点阐述离子通道蛋白的降解机制,并探讨通过控制离子通道蛋白降解机制的药物在心律失常治疗中的应用。